CLINICAL CARDIOLOGY临床心脏病学
CLINICAL CARDIOLOGY(英文缩写 CLIN CARDIOL),ISSN 0160-9289,eISSN 1932-8737,中文译名:临床心脏病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.287 | Q3 |
| 2022 | 2.700 | Q3 |
| 2023 | 2.400 | Q2 |
| 2024 | 2.300 | Q2 |
| 2025 | 2.800 | Q2 |
CLINICAL CARDIOLOGY 最新收录文献
-
1. Methodological Considerations Regarding the Comparison of Clevidipine and Nicardipine in Hypertensive Emergencies.
PMID:日期:2026-09-01该文献暂无摘要。
-
2. Antithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review.
PMID:日期:2026-09-01Coronary artery aneurysm (CAA), coronary artery ectasia (CAE), and coronary slow flow phenomenon (CSFP) are coronary pathologies associated with altered hemodynamics and increased thrombotic risk. However, optimal antithrombotic management remains uncertain because of limited and heterogeneous evidence. This systematic review aimed to synthesize data on the efficacy and safety of antiplatelet and anticoagulant therapies in patients with CAA, CAE, and CSFP. Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and ProQuest were searched through September 2025 for randomized and observational studies evaluating antithrombotic therapy in adults with these conditions. Outcomes included major adverse cardiovascular events and major bleeding. Narrative synthesis was conducted using the SWiM framework. Risk of bias was assessed using ROBINS-I and RoB 2.0, and certainty of evidence using GRADE. Eleven studies comprising 3271 participants were included: six on CAE (n = 895), four on CAA (n = 2356), and one on CSFP (n = 20). In CAE, dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC) were associated with fewer ischemic events than no therapy, although direct comparisons were inconsistent. The only randomized trial in CAE showed numerically lower recurrent myocardial infarction and cardiovascular death with single antiplatelet therapy (SAPT) plus direct oral anticoagulant (DOAC) versus DAPT, but findings were nonsignificant and based on few events. Evidence for CAA and CSFP remains limited and inconclusive. Intensified antithrombotic therapy may benefit patients with CAE, but evidence remains inconclusive for CAA and CSFP. Large, multicenter randomized trials are warranted to establish condition-specific treatment recommendations.
-
3. Long-Term Renal Function and Clinical Outcomes of Sacubitril/Valsartan in HFrEF and Stage 3-4 Chronic Kidney Disease: A 24-Month Single-Centre Cohort.
PMID:日期:2026-09-01Stage 3-4 chronic kidney disease (CKD) is common in heart failure with reduced ejection fraction (HFrEF) but remains underrepresented in angiotensin receptor-neprilysin inhibitor (ARNI) trials, fostering reluctance to initiate sacubitril/valsartan (S/V). We hypothesized that, over 24 months, S/V would be associated with stable renal function and acceptable clinical outcomes; the study was designed to be descriptive rather than comparative. We retrospectively analyzed 360 adults with HFrEF (LVEF < 40%) and predialysis stage 3-4 CKD who initiated S/V (2017-2023) and were followed for up to 24 months; decedents were analyzed as events, not excluded. The primary renal composite (sustained ≥ 30% eGFR decline, chronic dialysis, or end-stage kidney disease) was analyzed with competing-risk methods (Aalen-Johansen and Fine-Gray, with death competing); mortality with Cox regression; longitudinal eGFR with mixed-effects; and sparse-event models with Firth penalization. Among survivors, mean eGFR was stable (mixed-model slope non-significant), with no creatinine rise; NT-proBNP and CRP fell (both p < 0.001) and NYHA class improved. The renal composite occurred in 12/360 (3.3%); all-cause and cardiovascular mortality were 6.1% and 3.9%. Lower baseline eGFR was associated with the renal composite. Analyzes of maintenance dose and concomitant SGLT2-inhibitor use were confounded by treatment tolerance and calendar era and were hypothesis-generating only. In this single-arm cohort of HFrEF with stage 3-4 CKD, S/V was generally well tolerated, with stable renal function and low event rates over 24 months. These descriptive, hypothesis-generating findings cannot establish comparative benefit and require confirmation in controlled studies.
-
6. Outcomes of an Interventional Approach in STEMI and NSTEMI All-Comer Octo and Nonagenarians.
PMID:日期:2026-09-01The number of octogenarians and nonagenarians presenting with (NSTEMI) is rising. However, they are underrepresented in studies. Therefore, we aim to clarify patient characteristics and compare all-cause mortality of an initial invasive strategy versus optimal medical treatment in (N)STEMI octo and nonagenarians. All consecutive patients with (N)STEMI admitted from 2020 until 2023 were included. Patients were divided into invasive and OMT groups. Multi-variation corrected analyses were performed in two age groups. 775 consecutive patients > 80 years old were analyzed (81 > 90 years). A predominance of women, lower hemoglobin levels, eGFR, and lower rates of coronary angiography and PCI were observed in the nonagenarians. Six patients underwent CABG; all were in the 80-90-year age group. No differences existed in clinical complication rates between the groups. Invasive treatment demonstrated lower 1 year mortality, predominantly seen in NSTEMI elderly patients. In octo and nonagenarian (N)STEMI patients, stratifying to an invasive strategy with PCI/CABG appears to be feasible and is associated with improved mortality outcomes. This benefit is predominantly observed in patients with NSTEMI. Stratification can be done immediately on common clinical variables and appropriate shared decision-making.
-
7. Targeted Superior Vena Cava Isolation Combined With Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone Using Cryoballoon Ablation for Atrial Fibrillation.
PMID:日期:2026-09-01The superior vena cava (SVC) is a common non-pulmonary vein (non-PV) trigger site in atrial fibrillation (AF), but its triggers are frequently underdetected without systematic mapping and provocation maneuvers. This study aimed to assess the temporal trend in SVC trigger detection rates and compare the efficacy and safety of cryoballoon-based targeted SVC isolation combined with pulmonary vein isolation (PVI) versus PVI alone. A retrospective analysis was conducted on 990 consecutive patients who underwent cryoballoon ablation for AF between January 2020 and December 2024. Annual SVC trigger detection rates were assessed using the Cochran-Armitage trend test. After excluding redo cases and performing 1:1 propensity score matching, 55 matched pairs were compared in terms of procedural outcomes, complications, and 12-month freedom from atrial tachyarrhythmias. SVC trigger detection rates increased significantly over the study period, from 6.8% in 2020 to 21.3% in 2024 (P for trend = 0.023). After matching, the PVI + SVCI group showed significantly higher 12-month freedom from atrial tachyarrhythmias compared to the PVI-only group (90.9% vs. 76.4%, p = 0.037). Procedural time was modestly longer in the PVI + SVCI group (93 ± 26 min vs. 80 ± 20 min, p = 0.003), but fluoroscopy time (12 ± 5 min vs. 10 ± 4 min, p = 0.276) and complication rates (5.5% vs. 3.6%, p = 0.500) were comparable between groups, both with low overall complication rates. Cryoballoon-based targeted SVC isolation guided by systematic mapping and provocation maneuvers significantly enhances freedom from atrial tachyarrhythmias without compromising safety.
-
8. Closed-Loop AI Systems for Arrhythmia Management: Toward Predictive, Personalized, and Safe Cardiac Care.
PMID:日期:2026-09-01Cardiac arrhythmias impose a substantial global health and economic burden. Despite advances in electrophysiology and device-based therapy, management still depends on episodic monitoring and delayed decision-making, leaving a persistent gap between detection and intervention that is widest for intermittent and asymptomatic rhythm disturbances. This narrative review traces the shift from open-loop arrhythmia care to closed-loop, AI-assisted systems that couple continuous sensing, automated decision-making, and therapeutic actuation within a feedback-controlled architecture. Its contribution is to reframe arrhythmia AI around the control loop and its safety constraints rather than around detection accuracy alone, addressing a gap left by reviews that focus on classification algorithms or digital-twin modeling. We synthesized evidence from landmark device-programming trials, foundational work in control theory and machine learning, and current regulatory guidance to define the principles, technological basis, and system-level requirements of closed-loop arrhythmia care. As a narrative review, it emphasizes control logic, safety constraints, feedback, and clinical integration rather than algorithmic performance in isolation. Device-programming trials show that conservative timing, hierarchical escalation, and defined safety boundaries reduce inappropriate therapy and can improve survival, establishing the control principles on which AI systems must build. Machine learning extends these principles to scalable monitoring and adaptive decision-making but introduces concerns of stability, transparency, bias, and performance drift. Safe implementation therefore requires dependable sensing, bounded adaptation, supervisory control, and lifecycle evaluation. Closed-loop AI extends established electrophysiologic control principles rather than replacing clinical judgment. Embedded within transparent, governed architectures with bounded adaptation and human oversight, such systems may improve the personalization, safety, and outcomes of arrhythmia care.
-
9. Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results.
PMID:日期:2026-09-01Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a cornerstone therapy for HFrEF, significantly reducing hospitalizations and mortality regardless of glycemic status, sex, race, or comorbidities. EVOLUTION-HF was an observational, multi-center, longitudinal cohort study involving 257 consecutive patients diagnosed with HFrEF who initiated dapagliflozin in a routine clinical setting in Greece. The primary objectives were to characterize baseline demographic and clinical features of patients newly initiated on dapagliflozin for HFrEF and to evaluate dapagliflozin treatment patterns, including discontinuation timing, reasons for discontinuation, and concomitant heart failure and glucose-lowering therapies over time. The secondary objectives are to describe patient-reported outcomes using the KCCQ-23 and to assess adherence to dapagliflozin among patients with HFrEF. A total of 257 patients were enrolled and the follow-up period lasted for 12 months. Significant improvements among all KCCQ-23 scores were observed from baseline to 12-months post dapagliflozin initiation, revealing that the initiation and optimization of guideline-directed medical therapy in routine clinical practice provides improvement to quality of life over time. Dapagliflozin was safe and well-tolerated throughout the observation period. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow-up in these higher-risk groups.
-
10. Temporal Trends and Demographic Disparities in Mortality Due to Coronary Artery Disease and Hypertension in Adults Aged 25 and Above in the United States (2000 to 2024).
PMID:日期:2026-09-01Coronary artery disease (CAD) remains a leading cause of mortality, and hypertension serves as a primary, modifiable risk factor. While cardiovascular mortality historically declined, recent data indicate this trajectory has plateaued and begun to reverse. This study analyzes the temporal trends and demographic disparities in mortality due to CAD and hypertension among adults in the United States. This retrospective study utilized the CDC WONDER database to extract mortality data from 2000 to 2024. Deaths among adults aged 25 years and older with CAD and hypertension were identified. Age-adjusted mortality rates (AAMRs) per 100 000 population were calculated. Temporal patterns and annual percent change (APC) were evaluated using Joinpoint regression analysis. Between 2000 and 2024, 3 776 396 deaths occurred due to CAD and hypertension among US adults. Overall AAMR rose from 57.22 to 76.95, driven by a steep 2018-2021 increase (APC: 10.13%) before a recent decline (2021-2024, APC: -3.50%). By 2024, male AAMR (106.43) doubled female AAMR (52.68). Non-Hispanic African American adults experienced the highest AAMR (96.90). Non-metropolitan areas saw greater sustained increases (AAPC: 2.79%) than metropolitan areas (AAPC: 1.23%), with the South recording the highest regional AAMR (70.25; AAPC: 1.53%). While essential hypertension mortality stabilized, hypertensive heart disease (AAPC: 4.35%) and renal disease (AAPC: 8.83%) surged. Chronic ischemic heart disease remained the leading CAD subtype (AAPC: 1.37%). CAD and hypertension-related mortality among adults has increased significantly over the past 25 years, exposing significant demographic disparities. Targeted public health strategies prioritizing optimal blood pressure management and equitable healthcare access are essential to mitigate this escalating burden.